Posaconazole + ABT-199 + Decitabine + Azacitidine
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myelogenous Leukemia
Conditions
Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Trial Timeline
Oct 6, 2014 → Jun 16, 2022
NCT ID
NCT02203773About Posaconazole + ABT-199 + Decitabine + Azacitidine
Posaconazole + ABT-199 + Decitabine + Azacitidine is a phase 1 stage product being developed by AbbVie for Acute Myelogenous Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT02203773. Target conditions include Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myelogenous Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02203773 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myelogenous Leukemia